

# Correlation of human Bub1 expression with tumor-proliferating activity in salivary gland tumors

HIDEO SHIGEISHI<sup>1</sup>, SHINGO YONEDA<sup>1</sup>, MASAYUKI TAKI<sup>1</sup>, TAKESHI NOBUMORI<sup>1</sup>,  
KOUJI OHTA<sup>1</sup>, KOICHIRO HIGASHIKAWA<sup>1</sup>, WATARU YASUI<sup>2</sup> and NOBUYUKI KAMATA<sup>1</sup>

<sup>1</sup>Division of Cervico-Gnathostomatology, Department of Oral and Maxillofacial Surgery;

<sup>2</sup>Department of Molecular Pathology, Graduate School of Biomedical Sciences,  
Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan

Received November 28, 2005; Accepted January 10, 2006

**Abstract.** Human Bub1 plays an important role at the spindle assembly check-point to prevent cell cycle progression following spindle damage. We examined the expression of *Bub1* mRNA and protein in 21 human salivary gland tumors (7 pleomorphic adenomas, 2 warthin tumors, 5 mucoepidermoid carcinomas, 3 adenoid cystic carcinomas and 4 acinic cell carcinomas) and 3 normal submandibular glands using real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) or Western blotting. The mean expression levels of *Bub1* mRNA and protein were higher in malignant tumors ( $0.12 \pm 0.028/1.75 \pm 0.53$ ) than normal submandibular glands ( $0.042 \pm 0.014/0.19 \pm 0.044$ ) and benign tumors ( $0.058 \pm 0.01/0.97 \pm 0.44$ ). We found a significant association between the level of *Bub1* mRNA/protein expression and clinical stage in malignant tumors (Mann-Whitney U test,  $p=0.019/p=0.016$ ). We analyzed its relation with the proliferative activity monitored by the Ki-67 labeling index by immunohistochemistry as well as the expression of proliferating cell nuclear antigen (PCNA) by Western blotting. A significant correlation was found between *Bub1* mRNA/protein expression and the Ki-67 labeling index in salivary gland tumors (Spearman's correlation coefficient by rank test,  $p=0.026/p=0.002$ ). These results indicate that increased expression of the human *Bub1* gene is closely linked to abnormal cell proliferation in malignant conditions.

## Introduction

The spindle assembly check-point ensures fidelity chromosome segregation by delaying anaphase until all chromosomes are correctly attached to the spindle and increases

the probability of successful delivery of an euploid chromosome set to each daughter cell (1-3). Genetic studies in *Saccharomyces cerevisiae* have identified seven genes (*Bub1*, *Bub2*, *Bub3*, *Mad1*, *Mad2*, *Mad3* and *Mps1*) whose functions are required to properly arrest cell cycle progression following spindle damage (4,5). Among them, *Bub1* encodes a protein kinase that localizes to the kinetochore and can phosphorylate Bub3 protein (6). In the presence of spindle damage, Bub1 is required to prevent cell cycle progression into anaphase (7). Loss of Bub1 function causes cells to prematurely exit from mitosis (7).

Genetic alteration analyses of the *Bub1* gene have been reported to rarely occur in several human cancers (8-12). Overexpression of the *Bub1* gene has been reported in colorectal cancer (13). However, no study has been conducted to examine the expression of the *Bub1* gene in human salivary gland tumors.

In this study, we examined the expression of human Bub1, PCNA and Ki-67 in salivary gland tumors to clarify the correlation between Bub1 expression and cell proliferating activity.

## Materials and methods

**Tissue samples.** We examined 21 salivary gland tumors; seven pleomorphic adenomas, two warthin tumors, five mucoepidermoid carcinomas, three adenoid cystic carcinomas, and four acinic cell carcinomas (Tables I and II). Tumors were classified according to the criteria of the Armed Forces Institute of Pathology's classification of salivary gland tumors (14). Salivary gland tumor tissue and specimens of normal salivary glands were obtained with informed consent and approval from the institutional review board at Hiroshima University Dental Hospital (Japan). For molecular analyses, tissue samples obtained at the time of surgery were frozen immediately in liquid nitrogen and stored at  $-80^{\circ}\text{C}$ . We confirmed microscopically that the tumor specimens consisted mainly of carcinoma tissue and that the specimens of normal submandibular glands did not exhibit any tumor cell invasion or show significant inflammatory involvement.

**RNA extraction and quantitative RT-PCR analysis.** RNA was extracted using an RNeasy Mini Kit (Qiagen, Hilden,

---

**Correspondence to:** Dr Nobuyuki Kamata, Division of Cervico-Gnathostomatology, Department of Oral and Maxillofacial Surgery, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-855, Japan  
E-mail: nokam@hiroshima-u.ac.jp

**Key words:** Bub1, PCNA, Ki-67, salivary gland tumors

Table I. Expression of *Bub1* in normal submandibular glands and benign salivary gland tumors.

Case no.	Location <sup>a</sup>	Bub1 expression levels		PCNA <sup>d</sup>
		mRNA <sup>b</sup>	Protein <sup>c</sup>	
Normal submandibular gland				
1		0.024	0.19	0.053
2		0.071	0.26	ND
3		0.031	0.11	ND
Pleomorphic adenoma				
4	Palate	0.054	0.087	0.084
5	SMG	0.084	ND	ND
6	SMG	0.037	ND	ND
7	PG	0.054	ND	ND
8	Palate	0.04	0.55	0.21
9	Palate	0.025	0.87	0.30
10	PG	0.067	0.25	0.12
Warthin tumor				
11	PG	0.037	ND	ND
12	PG	0.12	3.03	3.63

<sup>a</sup>Location: SMG, submandibular gland; PG, palatid gland. <sup>b</sup>mRNA, level of mRNA expression was normalized with respect to internal control ( $\beta$ -actin). <sup>c</sup>Protein, level of protein expression was normalized with respect to internal control ( $\alpha$ -tubulin). <sup>d</sup>PCNA, level of PCNA protein expression was normalized with respect to internal control ( $\alpha$ -tubulin). ND, not determined.

Germany). Total RNA (1  $\mu$ g) was subjected to a reverse-transcriptase reaction using the First Strand cDNA Synthesis kit (Amersham Biosciences, Uppsala, Sweden). The quantification of mRNA levels was carried out using a real-time fluorescence detection method according to the method of Eads *et al* (15). The fluorescence was detected by the laser detector of the ABI PRISM 7700 Sequence Detection System (Perkin-Elmer, Foster city, CA) and the detection was carried out by measuring the binding of a fluorescence dye, SYBR-Green I, to double-stranded DNA. The PCR was run in microtubes in a volume of 25  $\mu$ l. The reaction mixture contained 1.0  $\mu$ g of cDNA, 10  $\mu$ l of SYBR-Green PCR Master Mix (Applied Biosystems), and 10 pmol of each pair of oligonucleotide primers. The primer sequences were: Bub1, 5'-TCATTCATGGAGACATTAAC-3' (sense), 5'-CTGAGCATCTCAACACACTG-3' (antisense); and  $\beta$ -actin, 5'-TGAGCGGGCTACAGCTT-3' (sense), 5'-CCTTAATGTCACACACGATT-3' (antisense). The PCR program was as follows: initial melting at 95°C for 10 min followed by 40 cycles at 95°C for 15 sec and 60°C for 60 sec. The quantification of Bub1 mRNA relative to an internal control,

$\beta$ -actin, was performed by the  $\Delta C_t$  method according to Tanaka *et al* (16). Results of the quantitative RT-PCR analysis of one salivary gland tumor sample are shown in Fig. 1.

**Protein extraction and Western blotting.** Protein extraction was carried out as described (17). The protein concentration was determined by the Bradford dye-binding protein assay (Bio-Rad, Richmond, CA) using bovine serum albumin (Sigma Chemical Co., St. Louis, MO ) as a standard. Protein samples (30  $\mu$ g) were solubilized in sample buffer by boiling and subjected to sodium dodecyl sulfate-poly-acrylamide gel electrophoresis (SDS-PAGE) followed by electrotransfer onto a nitrocellulose filter (Schleicher & Schuell, Dasse, Germany). Anti-human Bub1 monoclonal antibody (Chemicon, USA) and anti-human PCNA monoclonal antibody (MBL, Tokyo, Japan) were used in this study. The immune complex was detected using the ECL Western-blotting detection system (Amersham, Aylesbury, UK). Anti- $\alpha$ -tubulin mouse monoclonal antibody (Zymed Laboratories, South San Francisco, CA) was used as a positive control of Western blotting. Densitometric scanning was performed on signals normalized by the internal control ( $\alpha$ -tubulin).

**Immunohistochemistry.** Avidin-biotin-peroxidase complex immunostaining was performed as described previously (18). For the Ki-67 labeling index, immunohistochemical analysis was performed using an anti-Ki-67 monoclonal antibody (Dako, Copenhagen, Denmark). The proportion of tumor cell nuclei stained by Ki-67 was calculated for each tumor in x200 microscopic fields. All tumor cell nuclei stained brown above the background level, regardless of intensity, were considered positively stained. We presented the Ki-67 positive cell ratio as the number of tumor cells immunostained by Ki-67 per 1000 carcinoma cells in each case (Ki-67 labeling index). The Ki-67 labeling index was classified as low (<5%) or high ( $\geq$ 5%).

**Statistical methods.** The Mann-Whitney U test and Spearman's correlation coefficient by rank test were used for statistical analysis. P-values of <0.05 were regarded as statistically significant.

## Results

**Expression of Bub1 mRNA in salivary gland tumors.** We examined the expression of *Bub1* mRNA in 21 salivary gland tumors and 3 normal submandibular glands by real-time RT-PCR. The overall results are summarized in Tables I and II. The mean expression level of Bub1 mRNA was higher in malignant tumors (0.12 $\pm$ 0.028) than normal submandibular glands (0.042 $\pm$ 0.014) and benign tumors (0.058 $\pm$ 0.01) as shown in Fig. 2. Malignant tumors showed high levels of Bub1 mRNA expression compared to benign tumors, although the difference was not significant (Mann-Whitney U test, p=0.27). The expression of *Bub1* mRNA did not correlate with clinicopathological factors such as age, gender, tumor type and tumor location. Data on *Bub1* mRNA expression, tumor size, clinical stage and lymph node metastasis are summarized in Table III. A significant association was found

Case no.	Location <sup>a</sup>	Stage <sup>b</sup>	Meta <sup>c</sup>	Bub1 expression levels		PCNA <sup>f</sup>
				mRNA <sup>d</sup>	Protein <sup>e</sup>	
Mucoepidermoid carcinoma						
13	Mandibule	IV	-	0.22	4.96	1.95
14	PG	IV	+	0.12	4.19	1.95
15	Oral floor	II	-	0.053	0.72	1.09
16	Maxilla	IV	+	0.14	1.79	1.66
17	Mandibule	IV	+	0.08	ND	ND
Acinic cell carcinoma						
18	Maxilla	II	-	0.023	0.63	0.16
19	PG	I	-	0.067	0.64	0.33
20	PG	III	+	0.049	0.69	0.42
Adenoid cystic carcinoma						
21	Oral floor	III	+	0.30	2.94	1.06
22	Oral floor	II	-	0.061	0.36	0.47
23	Oral floor	I	-	0.048	0.60	0.97
24	Buccal mucosa	IV	-	0.29	ND	ND

<sup>a</sup>Location: PG, palotid gland. <sup>b</sup>Stage, tumor stages were determined according to the American Joint Committee on Cancer Staging Manual, 5th edition. <sup>c</sup>Meta: +, presence of lymph node metastasis; -, negative lymph node metastasis. <sup>d</sup>mRNA, level of mRNA expression was normalized with respect to internal control ( $\beta$ -actin). <sup>e</sup>Protein, level of protein expression was normalized with respect to internal control ( $\alpha$ -tubulin). <sup>f</sup>PCNA, level of PCNA protein expression was normalized with respect to internal control ( $\alpha$ -tubulin). ND, not determined.




Figure 1. Amplification curves of real-time quantitative PCR analysis of 1 salivary gland tumor sample: A,  $\beta$ -actin; B, *Bub1*; T, threshold;  $\Delta Rn$ , fluorescence of SYBR-Green I dye.

between the level of *Bub1* mRNA expression and clinical stage (Mann-Whitney U test,  $p=0.019$ ). Patients with larger tumors showed higher levels of *Bub1* mRNA expression and those with lymph node metastasis showed higher levels of *Bub1* mRNA expression than the patients without metastasis, although a significant association was not found in either case.

**Expression of *Bub1* and PCNA protein in salivary gland tumors.** We further analyzed the protein expression of *Bub1* and its relation with the proliferative activity monitored by the expression of proliferating cell nuclear antigen (PCNA)




Figure 2. Levels of *Bub1* mRNA expression in normal submandibular glands, benign salivary gland tumors and malignant salivary gland tumors: each point represents the *Bub1* mRNA expression level.

on Western blotting (Fig. 3). We performed densitometric scanning and normalized the signal intensities to an internal control ( $\alpha$ -tubulin expression). The overall results are summarized in Tables I and II. We found a significant association between expression levels of *Bub1* mRNA and protein in 3 submandibular glands and 15 salivary gland tumors (Mann-Whitney U test,  $p=0.023$ ). The mean expression

Table III. Expression of *Bub1* mRNA in salivary gland carcinomas and its correlation with clinicopathological parameters.

		Expression level of <i>Bub1</i>	
	Case no.	Mean $\pm$ SD	P-value <sup>b</sup>
Tumor size <sup>a</sup>			
T1	2	0.057 $\pm$ 0.01	0.12
T2	5	0.097 $\pm$ 0.05	
T4	5	0.17 $\pm$ 0.36	
Clinical stage <sup>a</sup>			
I + II	5	0.054 $\pm$ 0.007	0.019
III + IV	7	0.17 $\pm$ 0.037	
Lymph node metastasis			
Positive	5	1.55 $\pm$ 0.042	0.29
Negative	7	0.11 $\pm$ 0.038	

<sup>a</sup>According to the American Joint Committee on Cancer Staging Manual, 5th edition. <sup>b</sup>P-value, the correlation was analyzed using the Mann-Whitney U test and p-values are shown. P-values <0.05 were regarded as statistically significant.

Table IV. Expression of Bub1 protein in salivary gland carcinomas and its correlation with clinicopathological parameters.

		Expression level of Bub1	
	Case no.	Mean ± SD	P-value <sup>b</sup>
Tumor size <sup>a</sup>			
T1	2	0.62±0.018	0.11
T2	5	1.07±0.47	
T4	3	3.65±0.95	
Clinical stage <sup>a</sup>			
I + II	5	0.59±0.06	0.016
III + IV	5	2.91±0.78	
Lymph node metastasis			
Positive	4	2.41±0.75	0.14
Negative	6	1.32±0.73	

<sup>a</sup>According to the American Joint Committee on Cancer Staging Manual, 5th edition. <sup>b</sup>P-value, the correlation was analyzed using the Mann-Whitney U test and p values are shown. P-values <0.05 were regarded as statistically significant.




Figure 3. The expression of Bub1 and PCNA protein in normal submandibular glands and salivary gland tumors. The expression of  $\alpha$ -tubulin was used as a positive control of Western blotting.

level of Bub1 protein was higher in malignant tumors (1.75 $\pm$ 0.53) than normal submandibular glands (0.19 $\pm$ 0.044) and benign tumors (0.97 $\pm$ 0.44). Data on Bub1 protein expression, tumor size, clinical stage and lymph node metastasis are summarized in Table IV. A significant




Figure 4. Correlation between the Ki-67 labeling index and *Bub1* mRNA expression in salivary gland tumors. A significant correlation was found between the Ki-67 labeling index and *Bub1* (Spearman's correlation coefficient by rank test,  $p=0.026$ ).

association was found between the level of Bub1 protein expression and clinical stage (Mann-Whitney U test,  $p=0.016$ ). The expression levels of Bub1 protein correlated well with the levels of PCNA protein in one submandibular gland and 15 salivary gland tumors (Mann-Whitney U test,  $p=0.001$ ).

*Immunohistochemistry for Ki-67 in salivary gland tumors.* We further examined the expression of Ki-67 in salivary




Figure 5. Correlation between the Ki-67 labeling index and Bub1 protein expression in salivary gland tumors. A significant correlation was found between the Ki-67 labeling index and Bub1 protein (Spearman's correlation coefficient by rank test,  $p=0.002$ ).

gland tumors immunohistochemically to investigate the correlation between Bub1 expression and proliferating activity. The mean level of Ki-67 labeling index was higher in malignant tumors ( $12.8 \pm 3.86$ ) than benign tumors ( $4.68 \pm 1.67$ ). The index was compared with the expression levels of Bub1 in the tumors. The average *Bub1* mRNA expression in the cases with a high Ki-67 labeling index ( $\geq 5\%$ ) and with a low labeling index ( $< 5\%$ ) was  $0.16 \pm 0.04$  and  $0.049 \pm 0.006$ , respectively, indicating a significant correlation between the Ki-67 labeling index and Bub1 expression in salivary gland tumors (Spearman's correlation coefficient by rank test,  $p=0.026$ ) (Fig. 4). We also found a significant correlation between the expression levels of Bub1 protein and Ki-67 labeling index (Spearman's correlation coefficient by rank test,  $p=0.002$ ) (Fig. 5). These findings suggest that expression of the human *Bub1* gene is closely associated with tumor proliferating activity.

## Discussion

Chromosome segregation in mitosis depends on kinetochores, complex protein structures that assemble at the centromeres of chromosomes (19). The spindle assembly check-point ensures accurate segregation of chromosomes (1-3). The check-point is mediated by a signal transduction system comprised of Mad and Bub proteins (2,20). The human *Bub1* gene is a protein kinase which localizes to kinetochores very early in prophase and plays a surveillance role in preventing the missegregation of chromosomes (20,21). A significant number of paired sister chromatids fail to move to the metaphase plate and kinetochores on these chromatids appear to bind in Bub1 depleted human cells (22). These observations suggest that human Bub1 is essential for check-point control and for correct chromosome congression. Bub1 is also required for efficient kinetochore localization of BubR1 and Mad2 in human somatic cells (23). Bub1 plays a key role in the assembly of check-point proteins at the kinetochore.

Mutant forms of the *Bub1* gene were identified in colorectal cancer cell lines with chromosomal instability (24). However, mutational inactivation of the *Bub1* gene is a very

rare event and plays a very restricted role in human cancers including carcinomas of the digestive tract, breast and lung (8-11). We have also performed sequencing analysis of the human *Bub1* gene in several cases of gastric carcinoma and could not identify any mutations (12). These observations indicate that mutational inactivation of the *Bub1* gene rarely occurs in human cancers.

Ouyang *et al* reported that the human *Bub1* mRNA level was abundantly expressed in primary human tissue and cancer cells with a high mitotic index (7). We have reported that the expression levels of *Bub1* mRNA correlated with the levels of PCNA protein and Ki-67 labeling index in several human gastric carcinoma cases (25). Grabsch *et al* also reported that there was a statistically significant positive correlation between overexpression of Bub1, BubR1 or Bub3 and Ki-67 expression (26). These observations suggest that human *Bub1* mRNA is closely linked to cell proliferation in human gastric carcinomas. However, it is not known whether Bub1 expression levels reflect spindle check-point function in human cancers. Further investigations are required to establish whether there is an association between Bub1 expression levels and check-point function.

Salivary gland tumors are uncommon with a broad heterogeneity (27,28). The most common benign tumor is the pleomorphic adenoma, whereas mucoepidermoid carcinoma, adenoid cystic carcinoma and acinic cell carcinoma predominate among malignant tumors. In this study, we found that expression levels of *Bub1* mRNA and protein were higher in malignant salivary gland tumors than in benign salivary gland tumors and normal submandibular gland tissue. A significant association between expression levels of *Bub1* mRNA/protein and clinical stage was found in malignant salivary tumors. The results indicate that the *Bub1* gene is associated with tumor progression in malignant salivary gland tumors. Furthermore, we demonstrated a significant association between the expression level of *Bub1* mRNA/protein and the Ki-67 labeling index, which has been reported to correlate with the prognosis of various salivary gland carcinomas (29,30). PCNA, an auxiliary protein for DNA polymerase  $\delta$ , plays an important role in DNA synthesis and is thought to be localized to nuclei, particularly during late G and S phases (31,32). The expression of PCNA is a useful marker in evaluating the cell proliferating activity in human salivary gland tumors (33,34). In this study, Bub1 protein expression correlated with PCNA expression using Western blot analysis. We have also analyzed the expression levels of *BubR1* and *Bub3* mRNA in salivary gland tumors. The expression levels of *BubR1* and *Bub3* mRNA were higher in malignant salivary gland tumors than benign salivary gland tumors and normal submandibular gland tissue (Shigeishi *et al*, unpublished data). However, we could not find a significant association between the expression levels of *BubR1/Bub3* mRNA and the Ki-67 labeling index (Shigeishi *et al*, unpublished data). These results indicate that expression of the human *Bub1* gene is strongly associated with tumor-proliferating activity in human salivary gland carcinomas.

Bub1 is required for kinetochore localization of centromere protein-F (CENP-F) in human somatic cells (23). CENP-F is a kinetochore protein identified through the use of human autoimmune sera (35). CENP-F plays several important roles

in mitotic events, including centromere/kinetochore maturation, chromosome alignment and segregation, and anaphase spindle stabilization (36). We have already reported that human *CENP-F* mRNA is closely linked to the increased or abnormal cell proliferation in salivary gland carcinomas (37). The increased expression of Bub1 and CENP-F gene might cause cell cycle progression and high proliferative activity in malignant conditions.

Since the numbers of cases of each salivary gland carcinoma investigated in this study were relatively small, further analysis is needed to confirm the correlation between Bub1 expression and tumor-proliferating activity. The present study suggests the usefulness of the *Bub1* gene as an additional diagnostic tool for salivary gland carcinomas.

### Acknowledgements

This study was supported by a Grant-in-aid from the Japanese Ministry of Education, Culture, Sports and Technology.

### References

- Rudner AD and Murray AW: The spindle assembly checkpoint. *Curr Opin Cell Biol* 8: 773-780, 1996.
- Hoyt MA, Totis L and Roberts BT: *S. cerevisiae* genes required for cell cycle arrest in response to loss of microtubule function. *Cell* 66: 507-517, 1991.
- Pennisi E: Cell division gatekeepers identified. *Science* 279: 477-478, 1998.
- Roberts BT, Farr KA and Hoyt MA: The *Saccharomyces cerevisiae* spindle assembly checkpoint. *Mol Cell Biol* 14: 8282-8291, 1994.
- Farr KA and Hoyt MA: Bub1p kinase activates the *Saccharomyces* subjected to cytoplasmic dynein-mediated poleward transport. *Mol Cell Biol* 18: 2738-2747, 1998.
- Roberts BT, Farr KA and Hoyt MA: The *Saccharomyces cerevisiae* checkpoint gene BUB1 encodes a novel protein kinase. *Cell Growth Differ* 9: 877-885, 1998.
- Ouyang B, Lan Z, Meadows J, Pan H, Fukasawa K, Li W and Dai W: Human Bub1: a putative spindle checkpoint kinase closely linked to cell proliferation. *Curr Opin Cell Biol* 8: 773-780, 1996.
- Imai Y, Shiratori Y, Kato N, Inoue T and Omata M: Mutational inactivation of mitotic checkpoint genes, hSMAD2 and hBUB1, is rare in sporadic digestive tract cancers. *Jpn J Cancer Res* 90: 837-840, 1999.
- Myrie KA, Percy MJ, Azim JN, Neeley CK and Petty EM: Mutation and expression analysis of human BUB1 and BUB1B in aneuploid breast cancer cell lines. *Cancer Lett* 152: 193-199, 2000.
- Yamaguchi K, Okami K, Hibi K, Wehage SL, Jen J and Sidransky D: Mutation analysis of hBUB1 in aneuploid HNSCC and lung cancer cell lines. *Cancer Lett* 139: 183-187, 1999.
- Langerod A, Stromberg M, Chin K, Kristensen VN and Borresen-Dale AL: BUB1 infrequently mutated in human breast carcinomas. *Hum Mutat* 22: 420, 2003.
- Shigeishi H, Yokozaki H, Kuniyasu H, Nakagawa H, Ishikawa T, Tahara E and Yasui W: No mutations of the Bub1 gene in human gastric carcinomas. *Oncol Rep* 8: 791-794, 2001.
- Shichiri M, Yoshinaga K, Hisatomi H, Sugihara K and Hirata Y: Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. *Cancer Res* 62: 13-17, 2002.
- Ellis GL and Auclair PL: Tumors of the salivary glands. In: *Atlas of Tumor Pathology*. Rosai J and Sobin LH (eds). Armed Forces Institute of Pathology, Washington, DC, 1995.
- Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV and Laird PW: CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. *Cancer Res* 59: 2302-2306, 1999.
- Tanaka S, Kobayashi I, Utsuki S, Oka H, Fujii K and Watanabe T: O6-methylguanine-DNA methyltransferase gene expression in gliomas by means of real-time quantitative RT-PCR and clinical response to nitrosoureas. *Int J Cancer* 103: 67-72, 2003.
- Yasui W, Kuniyasu H, Yokozaki H, Semba S, Shimamoto F and Tahara E: Expression of cyclin E in colorectal adenomas and adenocarcinomas: correlation of Ki67 and p53 protein. *Virchows Arch* 429: 13-19, 1996.
- Kuniyasu H, Oue N, Shigeishi H, Ito R, Kato Y, Yokozaki H and Yasui W: Prospective study of Ki-67 labeling index in the mucosa adjacent to cancer as a marker for colorectal cancer metastasis. *J Exp Clin Cancer Res* 20: 543-548, 2001.
- Amon A: The spindle checkpoint. *Curr Opin Genet Dev* 9: 69-75, 1999.
- Lengauer C and Wang Z: From spindle checkpoint to cancer. *Nat Genet* 36: 1144-1145, 2004.
- Jablonski SA, Chan GK, Cooke CA, Earnshaw WC and Yen TJ: The hBUB1 and hBUBR1 kinases sequentially assemble onto kinetochores during prophase with hBUBR1 concentrating at the kinetochore plates in mitosis. *Chromosoma* 107: 386-396, 1998.
- Meraldi P and Sorger PK: A dual role for Bub1 in the spindle checkpoint and chromosome congression. *EMBO J* 24: 1621-1633, 2005.
- Johnson VL, Scott MI, Holt SV, Hussein D and Taylor SS: Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression. *J Cell Sci* 117: 1577-1589, 2004.
- Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW and Vogelstein B: Mutations of mitotic checkpoint genes in human cancers. *Nature* 392: 300-303, 1998.
- Shigeishi H, Oue N, Kuniyasu H, Wakikawa A, Yokozaki H, Ishikawa T and Yasui W: Expression of Bub1 gene correlates with tumor proliferating activity in human gastric carcinomas. *Pathobiology* 69: 24-29, 2001.
- Grabsch H, Takeno S, Parsons WJ, Pomjanski N, Boecking A, Gabbert HE and Mueller W: Overexpression of the mitotic checkpoint genes BUB1, BUBR1 and BUB3 in gastric cancer-association with tumour cell proliferation. *J Pathol* 200: 16-22, 2003.
- Eveson JW and Cawson RA: Salivary gland tumours. A review of 2410 cases with particular reference to histological types, site, age and sex distribution. *J Pathol* 146: 51-58, 1985.
- Spiro RH: Salivary neoplasms: overview of a 35-year experience with 2,807 patients. *Head Neck Surg* 8: 177-184, 1986.
- Hellquist HB, Sundelin K, Di Bacco A, Tytor M, Manzotti M and Viale G: Tumour growth fraction and apoptosis in salivary gland acinic cell carcinomas. Prognostic implications of Ki-67 and bcl-2 expression and of *in situ* end labelling (TUNEL). *J Pathol* 181: 323-329, 1997.
- Nordgard S, Franzen G, Boysen M and Halvorsen TB: Ki-67 as a prognostic marker in adenoid cystic carcinoma assessed with the monoclonal antibody MIB1 in paraffin sections. *Laryngoscope* 107: 531-536, 1997.
- Garcia RL, Coltrera MD and Grown AM: Analysis of proliferative grade using anti PCNA/cyclin in fixed, embedded tissues. *Am J Pathol* 134: 733-739, 1989.
- Landberg G, Tan EM and Roos G: Flow cytometric multiparameter analysis of proliferating cell nuclear antigen/cyclin and Ki-67 antigen. *Exp Cell Res* 187: 111-118, 1990.
- Skalova A and Leivo I: Cell proliferation in salivary gland tumors. *Gen Diagn Pathol* 142: 7-16, 1996.
- Russo G, Zamparelli A, Howard CM, Minimo C, Bellan C, Carillo G, Califano L, Leoncini L, Giordano A and Claudio PP: Expression of cell cycle-regulated proteins pRB2/p130, p107, E2F4, p27 and pCNA in salivary gland tumors: prognostic and diagnostic implications. *Clin Cancer Res* 11: 3265-3273, 2005.
- Rattner JB, Rao A, Fritzler MJ, Valencia DW and Yen TJ: CENP-F is a ca 400 kDa kinetochore protein that exhibits a cell-cycle dependent localization. *Cell Motil Cytoskeleton* 26: 214-226, 1993.
- Yang ZY, Guo J, Li N, Qian M, Wang SN and Zhu XL: Mitosin/CENP-F is a conserved kinetochore protein subjected to cytoplasmic dynein-mediated poleward transport. *Cell Res* 13: 275-283, 2003.
- Shigeishi H, Mizuta K, Higashikawa K, Yoneda S, Ono S and Kamata N: Correlation of CENP-F gene expression with tumor-proliferating activity in human salivary gland tumors. *Oral Oncol* 41: 716-722, 2005.